Sailong Pharmaceutical Group Co.,Ltd. (002898.SZ)

8.95 +0.06 (+0.67%) At close: 03:04PM CST

Sailong Pharmaceutical Group Co.,Ltd.

Everbright International Trade Center
West side of the second floor No. 47, Jida Haibin South Road Xiangzhou District
Zhuhai 519015
China
86 75 6388 2955
https://www.sailong.cn

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 483

Description

Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.

Corporate governance

Sailong Pharmaceutical Group Co.,Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.